BioCentury | Jan 16, 2021
Product Development
Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte
...the first-line setting.At the 2018 meeting of the American Society of Clinical Oncology, AstraZeneca plc (LSE:AZN...